A Phase II Study to Assess the Activity of PD-L1 Inhibition With Durvalumab (MEDI4736) After Chemo-Radiotherapy in Patients With Stage II-IV Microsatellite Stable (MSS) Rectal Cancer

Trial Profile

A Phase II Study to Assess the Activity of PD-L1 Inhibition With Durvalumab (MEDI4736) After Chemo-Radiotherapy in Patients With Stage II-IV Microsatellite Stable (MSS) Rectal Cancer

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Sep 2017

At a glance

  • Drugs Durvalumab (Primary)
  • Indications Adenocarcinoma; Rectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Sep 2017 Planned End Date changed from 1 Sep 2019 to 1 Dec 2019.
    • 07 Sep 2017 Planned primary completion date changed from 1 Sep 2019 to 1 Dec 2019.
    • 07 Sep 2017 Planned initiation date changed from 1 Jul 2017 to 1 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top